| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥170.3B | ¥138.4B | +23.1% |
| Operating Income / Operating Profit | ¥22.0B | ¥14.5B | +51.7% |
| Ordinary Income | ¥21.9B | ¥14.4B | +52.4% |
| Net Income / Net Profit | ¥15.3B | ¥9.6B | +60.1% |
| ROE | 7.7% | 4.9% | - |
FY2027 Q1 recorded revenue of ¥170.3B (YoY +¥31.9B +23.1%), Operating Income of ¥22.0B (YoY +¥7.5B +51.7%), Ordinary Income of ¥21.9B (YoY +¥7.5B +52.4%), and quarterly Net Income attributable to owners of the parent of ¥14.9B (YoY +¥5.3B +57.0%), representing revenue growth and substantial profit increase. Gross margin was 41.6% (up +3.0pt from 38.6% a year earlier) and Operating Margin was 12.9% (up +2.4pt from 10.5%), showing marked improvement in profitability. By segment, the core Creative Business (Japan) led growth with revenue of ¥105.9B (+14.1%) and Operating Income of ¥8.2B (+23.1%). The Medical Business recorded revenue of ¥22.4B (+15.7%) and Operating Income of ¥10.4B (+28.9%) with a high-margin structure (Operating Margin 46.3%), lifting company-wide margins. Progress toward the Full Year plan (Revenue ¥660.0B, Operating Income ¥54.5B) stands at 25.8% for Revenue and 40.4% for Operating Income, indicating profit progress ahead of schedule. Total assets were ¥444.9B (¥-23.5B vs. fiscal year-end), Net Assets were ¥198.3B (¥+4.1B vs. fiscal year-end) with an Equity Ratio of 44.6% and ROE of 7.7% (annualized). On the financing side, Long-term Borrowings increased to ¥11.9B (¥+9.2B vs. fiscal year-end) indicating an elongation of debt tenor, while Short-term Borrowings decreased to ¥101.5B (¥-10.2B) slightly reducing short-term dependence. Cash and Deposits stood at ¥179.1B, indicating ample liquidity, but Short-term Debt Ratio of 89.5% signals remaining maturity concentration risk.
[Revenue] Revenue of ¥170.3B was up +23.1% YoY. The Creative Business (Japan) grew to ¥105.9B (62.2% of total) up +14.1%, driving company-wide top-line growth. The Medical Business achieved ¥22.4B (13.2% of total) up +15.7%, maintaining high growth, and Other segments including CRES expanded to ¥17.5B vs. prior year. Creative Business (Korea) showed modest recovery at ¥8.0B (+5.2%), Accounting & Legal Business recorded ¥6.2B (+1.5%) with slight increase. External revenue after inter-segment eliminations rose +23.1% overall, led by strong performance in the two core segments (Japan Creative and Medical).
[Profitability] Cost of sales was ¥99.4B (YoY +¥14.4B), while Gross Profit was ¥70.9B (YoY +¥17.5B), resulting in a Gross Margin of 41.6% (up +3.0pt from 38.6%). This was supported by high-margin Medical Business and improved project mix. SG&A expenses increased to ¥48.9B (YoY +¥10.0B, +25.7%), but gross profit growth outpaced expenses, delivering Operating Income of ¥22.0B (YoY +51.7%). Operating Margin improved to 12.9% (up +2.4pt from 10.5%) reflecting operating leverage. Non-operating items were neutral (Interest Income ¥0.1B, Interest Expense ¥0.3B), producing Ordinary Income of ¥21.9B (YoY +52.4%) consistent with operating performance. Extraordinary gains/losses were minimal (gain ¥0.1B, loss ¥0.1B), resulting in Profit Before Tax of ¥21.9B and Income Taxes of ¥6.6B (effective tax rate 30.1%), and Net Income attributable to owners of the parent of ¥14.9B (YoY +57.0%). Net income attributable to non-controlling interests was ¥0.5B (prior year ¥0.1B), also increased, concluding a strong quarter of revenue growth and significant profit expansion.
Creative Business (Japan): Revenue ¥105.9B (+14.1%), Operating Income ¥8.2B (+23.1%), Operating Margin 7.7%. As the core segment, it accounted for 62.2% of company revenue and served as the pillar of volume growth. Medical Business: Revenue ¥22.4B (+15.7%), Operating Income ¥10.4B (+28.9%), Operating Margin 46.3%, extremely high margin; it represented 47.3% of company Operating Income and was the largest driver of improved profitability. Creative Business (Korea): Revenue ¥8.0B (+5.2%) but an Operating Loss of ¥0.2B (previously Operating Profit ¥0.04B) — turned to loss. Impact on the company is limited, but structural improvement is an issue. Accounting & Legal Business: Revenue ¥6.2B (+1.5%), Operating Income ¥0.5B (-5.7%), Operating Margin 7.4% down. Other including CRES: Revenue ¥11.6B (-13.7%) but Operating Income ¥0.1B (+125.7%) returned to profit, indicating progress in monetizing diversification areas. Company Operating Income of ¥22.0B equals the sum of segment profits plus adjustments of ¥0.0B, with the high margin in Medical Business lifting overall profitability.
[Profitability] Operating Margin was 12.9% (up +2.4pt from 10.5%), Net Margin was 9.0% (up +2.2pt from 6.8%), showing notable improvement. ROE of 7.7% on a quarterly basis annualizes to approximately 15.4%, indicating improving capital efficiency. Gross Margin was 41.6% (up +3.0pt from 38.6%), aided by high-margin Medical Business and improved project mix. [Cash Quality] Cash and Deposits ¥179.1B vs. Short-term Borrowings ¥101.5B, Cash/Short-term Debt ratio 1.76x, indicating ample on-hand liquidity. Accounts Receivable ¥100.5B equals about 59% of quarterly revenue ¥170.3B, implying a collection cycle of 215 days and signaling elongation; improving Cash Conversion is a challenge. [Investment Efficiency] Total Assets ¥444.9B vs. quarterly revenue ¥170.3B yields an annualized Total Asset Turnover of about 1.53x. Tangible Fixed Assets ¥32.0B (¥+6.8B vs. prior fiscal year-end, +27.1%), Investment Securities ¥41.6B (¥+18.3B vs. prior fiscal year-end, +78.6%), indicating parallel strengthening of business base and increased investment. Goodwill ¥3.9B is 2.0% of Net Assets and impairment risk is limited. [Financial Soundness] Equity Ratio 44.6% (up +3.1pt from 41.5% at prior fiscal year-end), D/E Ratio 1.24x (Interest-bearing liabilities total ¥113.8B / Equity ¥91.8B) at an appropriate level. Current Ratio 134.5%, Quick Ratio 134.4% indicate short-term liquidity coverage, but Short-term Debt Ratio 89.5% (Short-term Borrowings ¥101.5B / Interest-bearing Debt total ¥113.4B) leaves maturity concentration risk. Interest Coverage ~68x (Operating Income ¥22.0B / Interest Expense ¥0.3B) shows very high interest rate resilience.
Non-operating results were minor (Interest Income ¥0.1B, Interest Expense ¥0.3B), Extraordinary items were neutral (gain ¥0.1B, loss ¥0.1B), indicating that most current-period profit is operationally driven and recurring. Accounts Receivable of ¥100.5B declined from ¥111.6B at fiscal year-end but still represents about 59% of quarterly revenue ¥170.3B, translating to DSO of ~215 days and exhibiting a lengthening collection cycle. Work-in-progress ¥6.2B (¥3.0B at fiscal year-end) suggests an increase in progress-billed projects and concentration in acceptance timing, creating volatility in cash generation within the quarter. Cash and Deposits ¥179.1B remained flat vs. fiscal year-end ¥179.1B; despite recording quarterly Net Income of ¥14.9B, cash balance did not increase, suggesting simultaneous expansion of working capital and cash outflows for investments. Short-term Borrowings of ¥101.5B decreased from fiscal year-end ¥111.7B, while Long-term Borrowings increased to ¥11.9B from ¥2.7B (¥+9.2B), indicating progress in spreading maturities. Increase in Investment Securities (+¥18.3B) implies cash outflow in Investing CF, and dividends paid were zero as the company continues prioritizing internal funds for growth investments and working capital.
Ordinary Income ¥21.9B and Operating Income ¥22.0B are nearly identical, with non-operating items minor (Interest Income ¥0.1B, Interest Expense ¥0.3B, Other non-operating expenses ¥0.1B), indicating high core-business attribution of profits. Extraordinary items were largely neutral (gain on sale of investment securities ¥0.1B; loss on retirement of fixed assets and settlement payments each ¥0.0B), hence one-off impacts are limited. Comprehensive Income ¥14.9B versus Net Income ¥15.3B reflects FX translation adjustment -¥0.2B and Valuation difference on available-for-sale securities -¥0.1B, implying minor valuation losses and near alignment. Quarterly Net Income attributable to owners of the parent of ¥14.9B reflects an effective tax rate of 30.1% and represents a normal profit level; on accrual terms, prolonged Accounts Receivable collection cycle and increased Work-in-progress warrant attention for Operating Cash Flow quality, but the period profit itself is high-quality and likely sustainable.
Full Year plan: Revenue ¥660.0B (YoY +7.5%), Operating Income ¥54.5B (YoY +10.4%), Ordinary Income ¥53.5B (YoY +10.9%). Q1 results represent Revenue ¥170.3B (progress 25.8%), Operating Income ¥22.0B (progress 40.4%), Ordinary Income ¥21.9B (progress 40.9%), meaning profit progress is well ahead of the standard 25% benchmark. High margins in the Medical Business and profitability recovery in CRES contribute, increasing the likelihood of achieving full-year targets. However, accelerated progress may include effects of project acceptance timing and seasonality, so there is risk of reversal in H2. The earnings forecast was revised during the quarter, and the current Full Year plan reflects the latest view. Dividend forecast remains annual ¥0 (payout ratio 0%), with continued priority on internal reserves.
Annual dividend forecast is ¥0 (Payout Ratio 0%). The policy of prioritizing internal reserves for growth investments and working capital continues. Retained earnings ¥183.5B and Cash and Deposits ¥179.1B indicate strong capital and liquidity, and there is ample scope to resume dividends in the future, but current judgment is to prioritize profit growth and strengthening the business base. No buyback announcement has been made; shareholder returns are deferred for the time being. Resumption of dividends is likely contingent on normalization of Accounts Receivable collections and stabilization of Operating Cash Flow; future progress will be monitored.
Segment concentration risk: Creative Business (Japan) accounts for 62.2% of revenue, making the company sensitive to client conditions and advertising/production investment cycles. Although Medical Business accounts for only 13.2%, there is significant room to diversify into high-margin segments; however, dependency on the core business remains high.
Working capital risk: Accounts Receivable ¥100.5B equates to DSO ~215 days and has lengthened, and Work-in-progress ¥6.2B has doubled YoY. Uneven project progress and acceptance timing can cause large quarter-to-quarter swings in Operating Cash Flow, and prolonged collection could reduce cash conversion and increase interest burden.
Short-term debt concentration risk: Short-term Borrowings ¥101.5B (89.5% of interest-bearing debt) are concentrated in short maturities, increasing refinancing dependence. While Long-term Borrowings rose to ¥11.9B and maturity diversification is progressing, Short-term Debt Ratio remains high, necessitating caution regarding rising interest rates or deteriorating credit conditions which could increase funding costs and liquidity risk.
Profitability & Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 12.9% | 8.0% (2.2%–15.8%) | +4.9pt |
| Net Margin | 9.0% | 5.8% (1.5%–10.7%) | +3.2pt |
With a high-margin Medical Business, both Operating Margin and Net Margin materially exceed industry medians, positioning the company in the upper tier for profitability within the industry.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 23.1% | 9.3% (0.2%–16.9%) | +13.8pt |
Revenue growth of +23.1% substantially outpaces the industry median +9.3%, driven by expansion in core segments and high-margin areas.
※ Source: Company compilation
Expansion of the Medical Business (Operating Margin 46.3%) and profitability recovery in CRES contributed to improving the company Operating Margin to 12.9% (up +2.4pt from 10.5%). Profit progress versus the Full Year plan of 40.4% is well above standard progress, increasing the likelihood of achieving the full-year target. Continued increase in the proportion of high-margin segments could further boost Operating Margin and shareholder value.
Lengthening Accounts Receivable collection cycle (DSO ~215 days) and dependence on Short-term Borrowings (Short-term Debt Ratio 89.5%) are main concerns for working capital management and cash flow quality. Although Long-term Borrowings have increased and maturity extension is progressing, normalizing DSO and continuing maturity diversification are keys to strengthening financial resilience. Cash and Deposits ¥179.1B support liquidity, so near-term funding risks are limited.
The concentration structure with Creative Business (Japan) accounting for 62.2% of revenue increases sensitivity to client conditions and advertising cycles. Conversely, there is considerable room to expand the Medical Business, and diversification into high-margin areas would be a structural driver to enhance revenue stability and sustainable growth. Profitability improvement in the Korea business is also a point to watch.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company from public earnings data. Investment decisions are your responsibility; please consult professionals as needed before making investment decisions.